Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugene A Zhukovsky

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Opinion in Immunology|March 11, 2016
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirectionEugene A Zhukovsky, Richard J Morse, Marcela V Maus
Drug Discovery Today|November 13, 2007
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspectiveJohn R Desjarlais, Greg A Lazar, Eugene A Zhukovsky, et al.
Nature|January 30, 2004
TNF ligands: is TALL-1 a trimer or a virus-like cluster?Eugene A Zhukovsky, Jie-Oh Lee, Michael Villegas, et al.
Frontiers in Oncology|June 10, 2017
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb AntibodiesKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Blood|December 26, 2008
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primatesJonathan Zalevsky, Irene W L Leung, Sher Karki, et al.
Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Blood|July 10, 2010
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignanciesHolly M Horton, Matthew J Bernett, Matthias Peipp, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Opinion in Immunology|March 11, 2016
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirectionEugene A Zhukovsky, Richard J Morse, Marcela V Maus
Drug Discovery Today|November 13, 2007
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspectiveJohn R Desjarlais, Greg A Lazar, Eugene A Zhukovsky, et al.
Nature|January 30, 2004
TNF ligands: is TALL-1 a trimer or a virus-like cluster?Eugene A Zhukovsky, Jie-Oh Lee, Michael Villegas, et al.
Frontiers in Oncology|June 10, 2017
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb AntibodiesKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Blood|December 26, 2008
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primatesJonathan Zalevsky, Irene W L Leung, Sher Karki, et al.
Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Blood|July 10, 2010
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignanciesHolly M Horton, Matthew J Bernett, Matthias Peipp, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Pageof 2